4 transcripts
URGN
Earnings call transcript
NASDAQ
2024 Q2
13 Aug 24
of positive 12-month duration of response data from the ENVISION study evaluating UGN-102 in patients with low-grade intermediate risk, non-muscle
URGN
Earnings call transcript
NASDAQ
2024 Q1
13 May 24
us this morning. As we look ahead to 2024, we have several near-term catalysts, including the plan released of the 12-month duration of response data
URGN
Earnings call transcript
NASDAQ
2023 Q4
14 Mar 24
development plan for UGN-102, which includes evaluation of duration of complete response data at 12 months from the pivotal ENVISION trial, which support
URGN
Earnings call transcript
NASDAQ
2023 Q2
10 Aug 23
in the TURBT arm by Kaplan-Meier analysis. UGN-102 also showed a 65% complete response rate at 3 months for patients who only received UGN-102 compared to a 64
- Prev
- 1
- Next